Recommended PPI Dosing for Upper GI Bleeding

Initial Management of Upper GI Bleeding

The American College of Gastroenterology recommends high-dose PPI therapy with an 80 mg IV bolus followed by 8 mg/hour continuous infusion for 72 hours after successful endoscopic therapy to reduce rebleeding and mortality in patients with upper GI bleeding 1, 2, 3, 4
High-dose PPI therapy is strongly recommended for patients with bleeding ulcers with high-risk stigmata who have undergone successful endoscopic therapy 4
The standard high-dose regimen consists of an 80 mg IV bolus followed by continuous infusion at 8 mg/hour for 72 hours, which has been shown to significantly reduce rebleeding rates compared to H2-receptor antagonists or placebo 1, 2, 3

Empirical therapy with a high-dose PPI should be considered in patients awaiting endoscopy, based on biological plausibility and consensus, though with lower evidence quality (Grade C recommendation) 2, 3

After the initial 72 hours of high-dose IV therapy, twice-daily oral PPIs are suggested through day 14 for patients at high risk of rebleeding 4
After day 14, once-daily PPI therapy is appropriate 4

Multiple randomized trials have demonstrated that high-dose bolus and continuous-infusion PPIs reduce rebleeding and need for surgery compared with H2-receptor antagonists or placebo 1, 3
Meta-analyses confirm that high-dose PPI therapy after successful endoscopic therapy leads to statistically significant reduction in rebleeding rates 1, 3

PPI therapy is not a replacement for urgent endoscopy and hemostasis when appropriate 3
The benefits of PPI therapy are most pronounced in patients with high-risk endoscopic stigmata 1, 3
PPIs are specifically indicated for upper GI bleeding but not lower GI bleeding such as diverticular bleeding 5, 6

Testing for Helicobacter pylori should be performed in patients with upper GI bleeding, and eradication therapy provided if infection is present 3
Patients at low risk for rebleeding after endoscopy can be fed within 24 hours 3
For patients on cardiovascular prophylaxis with antiplatelet therapy who have had previous ulcer bleeding, PPI therapy is suggested to reduce recurrent bleeding risk 4